Antipsychotic-Induced Dopamine Supersensitivity Psychosis: Pharmacology, Criteria, and Therapy

Psychotherapy and Psychosomatics

Volumn 86, Issue 4, 2017, Pages 189-219

  Chouinard, Guy ^a,b,f   Samaha, Anne Noël ^c   Chouinard, Virginie Anne ^d,e   Peretti, Charles Siegfried ^f   Kanahara, Nobuhisa ^g   Takase, Masayuki ^g   Iyo, Masaomi ^g  

^a MCGILL UNIVERSITY   (Canada)

^b CENTRE DE RECHERCHE FERNAND SEGUIN   (Canada)

^c UNIVERSITÉ DE MONTRÉAL   (Canada)

^d MCLEAN HOSPITAL   (United States)

^e HARVARD MEDICAL SCHOOL   (United States)

^f HÔPITAL SAINT ANTOINE   (France)

^g CHIBA UNIVERSITY   (Japan)

Author keywords

Antipsychotic induced psychosis; Antipsychotics; Dopamine D 2 receptor supersensitivity; Dopamine supersensitivity psychosis; Drug induced psychoses; Rebound; Schizophrenia; Supersensitivity psychosis; Tardive dyskinesia

Indexed keywords

ALPRAZOLAM; ARIPIPRAZOLE; CENTRAL NERVOUS SYSTEM AGENTS; CHLORPROMAZINE; CLOBAZAM; CLONAZEPAM; CLOZAPINE; COCAINE; DIAMORPHINE; DIAZEPAM; DOPAMINE; DOPAMINE 2 RECEPTOR; FLUOXETINE; FLUPHENAZINE; HALOPERIDOL; LORAZEPAM; NEUROLEPTIC AGENT; OLANZAPINE; PALIPERIDONE; PAROXETINE; PEROSPIRONE; PERPHENAZINE; PROLACTIN; QUETIAPINE; RISPERIDONE; SEROTONIN NORADRENALIN REUPTAKE INHIBITOR; SEROTONIN UPTAKE INHIBITOR; SERTRALINE; TRIAZOLAM; UNINDEXED DRUG; DOPAMINE 2 RECEPTOR BLOCKING AGENT;

ANTIPSYCHOTIC INDUCED DOPAMINE SUPERSENSITIVITY PSYCHOSIS; ARTICLE; CONCEPTUAL FRAMEWORK; DISEASE CLASSIFICATION; DRUG CHOICE; DRUG DOSE REDUCTION; DRUG INDUCED DISEASE; DRUG SUBSTITUTION; DRUG WITHDRAWAL; HUMAN; MULTICENTER STUDY (TOPIC); NONHUMAN; PRACTICE GUIDELINE; PREVALENCE; PRIORITY JOURNAL; PSYCHOSIS; RANDOMIZED CONTROLLED TRIAL (TOPIC); REBOUND; RECEPTOR DENSITY; RELAPSE; SCHIZOPHRENIA; TARDIVE DYSKINESIA; THEORETICAL MODEL; WITHDRAWAL SYNDROME; BRAIN; METABOLISM;

ANTIPSYCHOTIC AGENTS; BRAIN; DOPAMINE; DOPAMINE D2 RECEPTOR ANTAGONISTS; HUMANS; PSYCHOSES, SUBSTANCE-INDUCED; RECEPTORS, DOPAMINE D2;

EID: 85021641993     PISSN: 00333190     EISSN: 14230348     Source Type: Journal    
DOI: 10.1159/000477313     Document Type: Article

References (222)

1. Chouinard G, Chouinard VA: Atypical antipsychotics: CATIE study, drug-induced movement disorder and resulting iatrogenic psychiatric-like symptoms, supersensitivity rebound psychosis and withdrawal discontinuation syndromes. Psychother Psychosom 2008; 77: 69-77.
2. Lieberman JA, Stroup TS, McEvoy JP, Swartz MS, Rosenheck RA, Perkins DO, Keefe RS, Davis SM, Davis CE, Lebowitz BD, Severe J, Hsiao JK; Clinical Antipsychotic Trials of Intervention Effectiveness Investigators: Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. N Engl J Med 2005; 353: 1209-1223.
3. Seeman P: Targeting the dopamine D2 receptor in schizophrenia. Expert Opin Ther Targets 2006; 10: 515-531.
4. Iyo M, Tadokoro S, Kanahara N, Hashimoto T, Niitsu T, Watanabe H, Hashimoto K: Optimal extent of dopamine D2 receptor occupancy by antipsychotics for treatment of dopamine supersensitivity psychosis and lateonset psychosis. J Clin Psychopharmacol 2013; 33: 398-404.
5. Kane JM: Treatment strategies to prevent relapse and encourage remission. J Clin Psychiatry 2007; 68(suppl 14):27-30.
6. Burt DR, Creese I, Snyder SH: Antischizophrenic drugs: chronic treatment elevates dopamine receptor binding in brain. Science 1977; 196: 326-328.
7. Creese I, Burt DR, Snyder SH: Dopamine receptor binding enhancement accompanies lesion-induced behavioral supersensitivity. Science 1977; 197: 596-598.
8. Charron A, Hage CE, Servonnet A, Samaha AN: 5-HT2 receptors modulate the expression of antipsychotic-induced dopamine supersensitivity. Eur Neuropsychopharmacol 2015; 25: 2381-2393.
9. Samaha AN, Reckless GE, Seeman P, Diwan M, Nobrega JN, Kapur S: Less is more: Antipsychotic drug effects are greater with transient rather than continuous delivery. Biol Psychiatry 2008; 64: 145-152.
10. Samaha AN, Seeman P, Stewart J, Rajabi H, Kapur S: "Breakthrough" dopamine supersensitivity during ongoing antipsychotic treatment leads to treatment failure over time. J Neurosci 2007; 27: 2979-2986.
11. Bedard AM, Maheux J, Levesque D, Samaha AN: Continuous, but not intermittent, antipsychotic drug delivery intensifies the pursuit of reward cues. Neuropsychopharmacology 2011; 36: 1248-1259.
12. Bedard AM, Maheux J, Levesque D, Samaha AN: Prior haloperidol, but not olanzapine, exposure augments the pursuit of reward cues: implications for substance abuse in schizophrenia. Schizophr Bull 2013; 39: 692-702.
13. El Hage C, Bedard AM, Samaha AN: Antipsychotic treatment leading to dopamine supersensitivity persistently alters nucleus accumbens function. Neuropharmacology 2015; 99: 715-725.
14. Chouinard G: Severe cases of neuroleptic-induced supersensitivity psychosis. Diagnostic criteria for the disorder and its treatment. Schizophr Res 1991; 5: 21-33.
15. Kirkpatrick B, Alphs L, Buchanan RW: The concept of supersensitivity psychosis. J Nerv Ment Dis 1992; 180: 265-270.
16. Seeman MV, Seeman P: Is schizophrenia a dopamine supersensitivity psychotic reaction? Prog Neuropsychopharmacol Biol Psychiatry 2014; 48: 155-160.
17. Seeman P: Schizophrenia and dopamine receptors. Eur Neuropsychopharmacol 2013; 23: 999-1009.
18. Silvestri S, Seeman MV, Negrete JC, Houle S, Shammi CM, Remington GJ, Kapur S, Zipursky RB, Wilson AA, Christensen BK, Seeman P: Increased dopamine D2 receptor binding after long-Term treatment with antipsychotics in humans: A clinical PET study. Psychopharmacology (Berl) 2000; 152: 174-180.
19. Chouinard G, Creese I, Boisvert D, Annable L, Bradwejn J, Jones B: High neuroleptic plasma levels in patients manifesting supersensitivity psychosis. Biol Psychiatry 1982; 17: 849-852.
20. Miller R, Chouinard G: Loss of striatal cholinergic neurons as a basis for tardive and L-DOPA-induced dyskinesias, neurolepticinduced supersensitivity psychosis and refractory schizophrenia. Biol Psychiatry 1993; 34: 713-738.
21. Chouinard G, Jones BD: Schizophrenia as dopamine-deficiency disease. Lancet 1978; 2: 99-100.
22. Chouinard G, Jones BD: Evidence of brain dopamine deficiency in schizophrenia. Can J Psychiatry 1979; 24: 661-667.
23. Reith J, Benkelfat C, Sherwin A, Yasuhara Y, Kuwabara H, Andermann F, Bachneff S, Cumming P, Diksic M, Dyve SE, Etienne P, Evans AC, Lal S, Shevell M, Savard G, Wong DF, Chouinard G, Gjedde A: Elevated dopa decarboxylase activity in living brain of patients with psychosis. Proc Natl Acad Sci USA 1994; 91: 11651-11654.
24. Abi-Dargham A, Rodenhiser J, Printz D, Zea-Ponce Y, Gil R, Kegeles LS, Weiss R, Cooper TB, Mann JJ, Van Heertum RL, Gorman JM, Laruelle M: Increased baseline occupancy of D2 receptors by dopamine in schizophrenia. Proc Natl Acad Sci USA 2000; 97: 8104-8109.
25. Seeman P, Weinshenker D, Quirion R, Srivastava LK, Bhardwaj SK, Grandy DK, Premont RT, Sotnikova TD, Boksa P, El-Ghundi M, ODowd BF, George SR, Perreault ML, Mannisto PT, Robinson S, Palmiter RD, Tallerico T: Dopamine supersensitivity correlates with D2 High states, implying many paths to psychosis. Proc Natl Acad Sci USA 2005; 102: 3513-3518.
26. Seeman P: All roads to schizophrenia lead to dopamine supersensitivity and elevated dopamine D2 High receptors. CNS Neurosci Ther 2011; 17: 118-132.
27. George SR, Watanabe M, Di Paolo T, Falardeau P, Labrie F, Seeman P: The functional state of the dopamine receptor in the anterior pituitary is in the high affinity form. Endocrinology 1985; 117: 690-697.
28. Chouinard G, Jones BD, Annable L: Neuroleptic-induced supersensitivity psychosis. Am J Psychiatry 1978; 135: 1409-1410.
29. Davis KL, Rosenberg GS: Is there a limbic system equivalent of tardive dyskinesia? Biol Psychiatry 1979; 14: 699-703.
30. Chouinard G, Jones BD: Neuroleptic-induced supersensitivity psychosis: clinical and pharmacologic characteristics. Am J Psychiatry 1980; 137: 16-21.
31. Chouinard G: New nomenclature for druginduced movement disorders including tardive dyskinesia. J Clin Psychiatry 2004; 65: 9S-15S.
32. Moncrieff J: Why is it so difficult to stop psychiatric drug treatment? It may be nothing to do with the original problem. Med Hypotheses 2006; 67: 517-523.
33. Moncrieff J: Does antipsychotic withdrawal provoke psychosis? Review of the literature on rapid onset psychosis (supersensitivity psychosis) and withdrawal-related relapse. Acta Psychiatr Scand 2006; 114: 3-13.
34. Kimura H, Kanahara N, Komatsu N, Ishige M, Muneoka K, Yoshimura M, Yamanaka H, Suzuki T, Komatsu H, Sasaki T, Hashimoto T, Hasegawa T, Shiina A, Ishikawa M, Sekine Y, Shiraishi T, Watanabe H, Shimizu E, Hashimoto K, Iyo M: A prospective comparative study of risperidone long-Acting injectable for treatment-resistant schizophrenia with dopamine supersensitivity psychosis. Schizophr Res 2014; 155: 52-58.
35. Suzuki T, Kanahara N, Yamanaka H, Takase M, Kimura H, Watanabe H, Iyo M: Dopamine supersensitivity psychosis as a pivotal factor in treatment-resistant schizophrenia. Psychiatry Res 2015; 227: 278-282.
36. Takase M, Kanahara N, Oda Y, Kimura H, Watanabe H, Iyo M: Dopamine supersensitivity psychosis and dopamine partial agonist: A retrospective survey of failure of switching to aripiprazole in schizophrenia. J Psychopharmacol 2015; 29: 383-389.
37. Fallon P, Dursun SM: A naturalistic controlled study of relapsing schizophrenic patients with tardive dyskinesia and supersensitivity psychosis. J Psychopharmacol 2011; 25: 755-762.
38. Fallon P, Dursun S, Deakin B: Drug-induced supersensitivity psychosis revisited: characteristics of relapse in treatment-compliant patients. Ther Adv Psychopharmacol 2012; 2: 13-22.
39. Margolese HC, Chouinard G, Beauclair L, Belanger MC: Therapeutic tolerance and rebound psychosis during quetiapine maintenance monotherapy in patients with schizophrenia and schizoaffective disorder. J Clin Psychopharmacol 2002; 22: 347-352.
40. Ekblom B, Eriksson K, Lindstrom LH: Supersensitivity psychosis in schizophrenic patients after sudden clozapine withdrawal. Psychopharmacology (Berl) 1984; 83: 293-294.
41. Chouinard G, Chouinard VA: New classification of selective serotonin reuptake inhibitor withdrawal. Psychother Psychosom 2015; 84: 63-71.
42. Sasaki H, Hashimoto K, Maeda Y, Inada T, Kitao Y, Fukui S, Iyo M: Rolipram, a selective c-AMP phosphodiesterase inhibitor suppresses oro-facial dyskinetic movements in rats. Life Sci 1995; 56:PL443-PL447.
43. Sasaki H, Hashimoto K, Inada T, Fukui S, Iyo M: Suppression of oro-facial movements by rolipram, a cAMP phosphodiesterase inhibitor, in rats chronically treated with haloperidol. Eur J Pharmacol 1995; 282: 71-76.
44. Tadokoro S, Okamura N, Sekine Y, Kanahara N, Hashimoto K, Iyo M: Chronic treatment with aripiprazole prevents development of dopamine supersensitivity and potentially supersensitivity psychosis. Schizophr Bull 2012; 38: 1012-1020.
45. Lerer B, Jabotinsky-Rubin K, Bannet J, Ebstein RP, Belmaker RH: Electroconvulsive shock prevents dopamine receptor supersensitivity. Eur J Pharmacol 1982; 80: 131-134.
46. Smith RC, Davis JM: Behavioral evidence for supersensitivity after chronic administration of haloperidol, clozapine, and thioridazine. Life Sci 1976; 19: 725-731.
47. Turrone P, Remington G, Kapur S, Nobrega JN: The relationship between dopamine D2 receptor occupancy and the vacuous chewing movement syndrome in rats. Psychopharmacology (Berl) 2003; 165: 166-171.
48. ODell SJ, La Hoste GJ, Widmark CB, Shapiro RM, Potkin SG, Marshall JF: Chronic treatment with clozapine or haloperidol differentially regulates dopamine and serotonin receptors in rat brain. Synapse 1990; 6: 146-153.
49. Wilmot CA, Szczepanik AM: Effects of acute and chronic treatments with clozapine and haloperidol on serotonin (5-HT 2 ) and dopamine (D 2 ) receptors in the rat brain. Brain Res 1989; 487: 288-298.
50. Ginovart N, Wilson AA, Hussey D, Houle S, Kapur S: D 2-receptor upregulation is dependent upon temporal course of D 2-occupancy: A longitudinal [ 11 C]-raclopride PET study in cats. Neuropsychopharmacology 2009; 34: 662-671.
51. Huang N, Ase AR, Hebert C, van Gelder NM, Reader TA: Effects of chronic neuroleptic treatments on dopamine D 1 and D 2 receptors: homogenate binding and autoradiographic studies. Neurochem Int 1997; 30: 277-290.
52. Muller P, Seeman P: Dopaminergic supersensitivity after neuroleptics: Time-course and specificity. Psychopharmacology (Berl) 1978; 60: 1-11.
53. Marin C, Chase TN: Dopamine D 1 receptor stimulation but not dopamine D 2 receptor stimulation attenuates haloperidol-induced behavioral supersensitivity and receptor upregulation. Eur J Pharmacol 1993; 231: 191-196.
54. Ase AR, Amdiss F, Hebert C, Huang N, van Gelder NM, Reader TA: Effects of antipsychotic drugs on dopamine and serotonin contents and metabolites, dopamine and serotonin transporters, and serotonin1A receptors. J Neural Transm (Vienna) 1999; 106: 75-105.
55. Rivest R, Falardeau P, Di Paolo T: Brain dopamine transporter: gender differences and effect of chronic haloperidol. Brain Res 1995; 692: 269-272.
56. Thompson JL, Urban N, Slifstein M, Xu X, Kegeles LS, Girgis RR, Beckerman Y, Harkavy-Friedman JM, Gil R, Abi-Dargham A: Striatal dopamine release in schizophrenia comorbid with substance dependence. Mol Psychiatry 2013; 18: 909-915.
57. Chesi AJ, Feasey-Truger KJ, Alzheimer C, ten Bruggencate G: Dopamine autoreceptor sensitivity is unchanged in rat nucleus accumbens after chronic haloperidol treatment: An in vivo and in vitro voltammetric study. Eur J Neurosci 1995; 7: 2450-2457.
58. Ichikawa J, Meltzer HY: The effect of chronic atypical antipsychotic drugs and haloperidol on amphetamine-induced dopamine release in vivo. Brain Res 1992; 574: 98-104.
59. Seeman P, Schwarz J, Chen JF, Szechtman H, Perreault M, McKnight GS, Roder JC, Quirion R, Boksa P, Srivastava LK, Yanai K, Weinshenker D, Sumiyoshi T: Psychosis pathways converge via D 2 High dopamine receptors. Synapse 2006; 60: 319-346.
60. Seeman P, Guan HC: Dopamine partial agonist action of (-)OSU6162 is consistent with dopamine hyperactivity in psychosis. Eur J Pharmacol 2007; 557: 151-153.
61. Seeman P: Dopamine D 2 High receptors moderately elevated by sertindole. Synapse 2008; 62: 389-393.
62. Seeman P: Dopamine D 2 High receptors moderately elevated by bifeprunox and aripiprazole. Synapse 2008; 62: 902-908.
63. Graff-Guerrero A, Mizrahi R, Agid O, Marcon H, Barsoum P, Rusjan P, Wilson AA, Zipursky R, Kapur S: The dopamine D 2 receptors in high-Affinity state and D 3 receptors in schizophrenia: A clinical [ 11 C]-(+)-PHNO PET study. Neuropsychopharmacology 2009; 34: 1078-1086.
64. Seeman P: Dopamine agonist radioligand binds to both D 2 High and D 2 Low receptors, explaining why alterations in D 2 High are not detected in human brain scans. Synapse 2012; 66: 88-93.
65. Cho D, Zheng M, Min C, Ma L, Kurose H, Park JH, Kim KM: Agonist-induced endocytosis and receptor phosphorylation mediate resensitization of dopamine D 2 receptors. Mol Endocrinol 2010; 24: 574-586.
66. Rogue P, Hanauer A, Zwiller J, Malviya AN, Vincendon G: Up-regulation of dopamine D 2 receptor mRNA in rat striatum by chronic neuroleptic treatment. Eur J Pharmacol 1991; 207: 165-168.
67. Oda Y, Tadokoro S, Takase M, Kanahara N, Watanabe H, Shirayama Y, Hashimoto K, Iyo M: G protein-coupled receptor kinase 6/β-Arrestin 2 system in a rat model of dopamine supersensitivity psychosis. J Psychopharmacol 2015; 29: 1308-1313.
68. Oda Y, Kanahara N, Iyo M: Alterations of dopamine D 2 receptors and related receptor-interacting proteins in schizophrenia: The pivotal position of dopamine supersensitivity psychosis in treatment-resistant schizophrenia. Int J Mol Sci 2015; 16: 30144-30163.
69. Chouinard G, Sultan S: Treatment of neuroleptic-induced supersensitivity psychosis with antiepileptic drugs: report of a series of 43 cases. Psychopharmacol Bull 1990; 26: 337-341.
70. Schooler NR, Kane JM: Research diagnoses for tardive dyskinesia. Arch Gen Psychiatry 1982; 39: 486-487.
71. Chouinard G, Annable L, Ross-Chouinard A, Mercier P: A 5-year prospective longitudinal study of tardive dyskinesia: factors predicting appearance of new cases. J Clin Psychopharmacol 1988; 8: 21S-26S.
72. Chouinard G, Annable L, Ross-Chouinard A: Supersensitivity psychosis and tardive dyskinesia: A survey in schizophrenic outpatients. Psychopharmacol Bull 1986; 22: 891-896.
73. Chouinard G, Miller R: A Rating Scale for Psychotic Symptoms (RSPS) part I: Theoretical principles and subscale 1: perception symptoms (illusions and hallucinations). Schizophr Res 1999; 38: 101-122.
74. Chouinard G, Miller R: A Rating Scale for Psychotic Symptoms (RSPS): part II: subscale 2: distraction symptoms (catatonia and passivity experiences subscale 3: delusions and semi-structured interview (SSCI-RSPS). Schizophr Res 1999; 38: 123-150.
75. Juarez-Reyes MG, Shumway M, Battle C, Bacchetti P, Hansen MS, Hargreaves WA: Clozapine eligibility: The effect of stringent criteria on ethnic, gender and age subgroups of schizophrenic patients. Prog Neuropsychopharmacol Biol Psychiatry 1996; 20: 1341-1352.
76. Juarez-Reyes MG, Shumway M, Battle C, Bacchetti P, Hansen MS, Hargreaves WA: Effects of stringent criteria on eligibility for clozapine among public mental health clients. Psychiatr Serv 1995; 46: 801-806.
77. Carpenter WT Jr, Heinrichs DW, Wagman AM: Deficit and nondeficit forms of schizophrenia: The concept. Am J Psychiatry 1988; 145: 578-583.
78. Kolalowska T: Brief Psychiatric Rating Scale. Glossaries and Rating Instructions. Oxford, Oxford University, 1976.
79. Inada T: Recent research trends in diagnosis, treatment, and prevention of drug-induced extrapyramidal symptoms seen in psychiatric patients (in Japanese). Nihon Shinkei Seishin Yakurigaku Zasshi 1996; 16: 181-185.
80. Inada T, Inagaki A: Psychotropic dose equivalence in Japan. Psychiatry Clin Neurosci 2015; 69: 440-447.
81. Chouinard G, Margolese HC: Manual for the Extrapyramidal Symptom Rating Scale (ESRS). Schizophr Res 2005; 76: 247-265.
82. Chouinard G, Ross-Chouinard A, Annable L, Jones BD: Extrapyramidal symptom rating scale. Can J Neurol Sci 1980; 7: 233.
83. Overall J, Gorham DR: The Brief Psychiatric Rating Scale. Psychol Rep 1962; 10: 799-812.
84. Kimura H, Kanahara N, Sasaki T, Komatsu N, Ishige M, Muneoka K, Ino H, Yoshimura K, Yamanaka H, Suzuki T, Komatsu H, Watanabe H, Shimizu E, Iyo M: Risperidone longacting injectable in the treatment of treatment-resistant schizophrenia with dopamine supersensitivity psychosis: results of a 2-year prospective study, including an additional 1-year follow-up. J Psychopharmacol 2016; 30: 795-802.
85. Wing J, Cooper JE, Sartorius N: Measurement and Classification of Psychiatric Symptoms. Cambridge, Cambridge University Press, 1974.
86. Guy W: ECDEU Assessment Manual for Psychopharmacology, revised. Washington, US Department of Health, Education, and Welfare, 1976.
87. Brown GW, Harris T: Social Origins of Depression: A Study of Psychiatric Disorder in Women. London, Tavistock, 1978.
88. Fallon P: The role of intrusive and other recent life events on symptomatology in relapses of schizophrenia: A community nursing investigation. J Psychiatr Ment Health Nurs 2009; 16: 685-693.
89. Chouinard G: Rebound anxiety: incidence and relationship to subjective cognitive impairment. J Clin Psychiatry Monograph 1986; 4: 12-16.
90. Chouinard G: Issues in the clinical use of benzodiazepines: potency, withdrawal, and rebound. J Clin Psychiatry 2004; 65(suppl 5):7-12.
91. Fava GA, Gatti A, Belaise C, Guidi J, Offidani E: Withdrawal symptoms after selective serotonin reuptake inhibitor discontinuation: A systematic review. Psychother Psychosom 2015; 84: 72-81.
92. Schatzberg AF, Blier P, Delgado PL, Fava M, Haddad PM, Shelton RC: Antidepressant discontinuation syndrome: consensus panel recommendations for clinical management and additional research. J Clin Psychiatry 2006; 67(suppl 4):27-30.
93. Tranter R, Healy D: Neuroleptic discontinuation syndromes. J Psychopharmacol 1998; 12: 401-406.
94. Cerovecki A, Musil R, Klimke A, Seemuller F, Haen E, Schennach R, Kuhn KU, Volz HP, Riedel M: Withdrawal symptoms and rebound syndromes associated with switching and discontinuing atypical antipsychotics: Theoretical background and practical recommendations. CNS Drugs 2013; 27: 545-572.
95. Brower KJ: Alcohols effects on sleep in alcoholics. Alcohol Res Health 2001; 25: 110-125.
96. Shammash JB, Trost JC, Gold JM, Berlin JA, Golden MA, Kimmel SE: Perioperative betablocker withdrawal and mortality in vascular surgical patients. Am Heart J 2001; 141: 148-153.
97. Stevenson E, Schembri F, Green DM, Burns JD: Serotonin syndrome associated with clozapine withdrawal. JAMA Neurol 2013; 70: 1054-1055.
98. Hu WW, Fang Q, Xu ZH, Yan HJ, He P, Zhong K, Fan YY, Yang Y, Zhang XN, Zhang CY, Ohtsu H, Xu TL, Chen Z: Chronic H1-Antihistamine treatment increases seizure susceptibility after withdrawal by impairing glutamine synthetase. CNS Neurosci Ther 2012; 18: 683-690.
99. Nattel S, Rangno RE, Van Loon G: Mechanism of propranolol withdrawal phenomena. Circulation 1979; 59: 1158-1164.
100. Luchins DJ, Freed WJ, Wyatt RJ: The role of cholinergic supersensitivity in the medical symptoms associated with withdrawal of antipsychotic drugs. Am J Psychiatry 1980; 137: 1395-1398.
101. Shiovitz TM, Welke TL, Tigel PD, Anand R, Hartman RD, Sramek JJ, Kurtz NM, Cutler NR: Cholinergic rebound and rapid onset psychosis following abrupt clozapine withdrawal. Schizophr Bull 1996; 22: 591-595.
102. Houston MC, Hodge R: Beta-Adrenergic blocker withdrawal syndromes in hypertension and other cardiovascular diseases. Am Heart J 1988; 116: 515-523.
103. Fontaine R, Chouinard G, Annable L: Rebound anxiety in anxious patients after abrupt withdrawal of benzodiazepine treatment. Am J Psychiatry 1984; 141: 848-852.
104. Kales A, Bixler EO, Tan TL, Scharf MB, Kales JD: Chronic hypnotic-drug use. Ineffectiveness, drug-withdrawal insomnia, and dependence. JAMA 1974; 227: 513-517.
105. Kales A, Scharf MB, Kales JD: Rebound insomnia: A new clinical syndrome. Science 1978; 201: 1039-1041.
106. Oswald I, Priest RG: Five weeks to escape the sleeping-pill habit. Br Med J 1965; 2: 1093-1095.
107. Kales A, Preston TA, Tan TL, Allen C: Hypnotics and altered sleep-dream patterns. I. All-night EEG studies of glutethimide, methyprylon, and pentobarbital. Arch Gen Psychiatry 1970; 23: 211-218.
108. Miller RR, Olson HG, Amsterdam EA, Mason DT: Propranolol-withdrawal rebound phenomenon. Exacerbation of coronary events after abrupt cessation of antianginal therapy. N Engl J Med 1975; 293: 416-418.
109. Bhanji NH, Chouinard G, Kolivakis T, Margolese HC: Persistent tardive rebound panic disorder, rebound anxiety and insomnia following paroxetine withdrawal: A review of rebound-withdrawal phenomena. Can J Clin Pharmacol 2006; 13:e69-e74.
110. Rosenbaum JF, Fava M, Hoog SL, Ascroft RC, Krebs WB: Selective serotonin reuptake inhibitor discontinuation syndrome: A randomized clinical trial. Biol Psychiatry 1998; 44: 77-87.
111. Michelson D, Fava M, Amsterdam J, Apter J, Londborg P, Tamura R, Tepner RG: Interruption of selective serotonin reuptake inhibitor treatment. Double-blind, placebocontrolled trial. Br J Psychiatry 2000; 176: 363-368.
112. Cloos JM, Bocquet V, Rolland-Portal I, Koch P, Chouinard G: Hypnotics and triazolobenzodiazepines-best predictors of high-dose benzodiazepine use: results from the Luxembourg National Health Insurance Registry. Psychother Psychosom 2015; 84: 273-283.
113. Mendelson JH, Mello NK: Management of cocaine abuse and dependence. N Engl J Med 1996; 334: 965-972.
114. Kosten TR, OConnor PG: Management of drug and alcohol withdrawal. N Engl J Med 2003; 348: 1786-1795.
115. Markowitz JS, Brown CS, Moore TR: Atypical antipsychotics. Part I: Pharmacology, pharmacokinetics, and efficacy. Ann Pharmacother 1999; 33: 73-85.
116. Kapur S, Seeman P: Does fast dissociation from the dopamine D 2 receptor explain the action of atypical antipsychotics? A new hypothesis. Am J Psychiatry 2001; 158: 360-369.
117. Bandelow B, Chouinard G, Bobes J, Ahokas A, Eggens I, Liu S, Eriksson H: Extendedrelease quetiapine fumarate (quetiapine XR): A once-daily monotherapy effective in generalized anxiety disorder. Data from a randomized, double-blind, placebo-And active-controlled study. Int J Neuropsychopharmacol 2010; 13: 305-320.
118. Sanford M: Quetiapine extended release: Adjunctive treatment in major depressive disorder. CNS Drugs 2011; 25: 803-813.
119. Mamo DC, Uchida H, Vitcu I, Barsoum P, Gendron A, Goldstein J, Kapur S: Quetiapine extended-release versus immediate-release formulation: A positron emission tomography study. J Clin Psychiatry 2008; 69: 81-86.
120. Seeman P, Tallerico T: Rapid release of antipsychotic drugs from dopamine D 2 receptors: An explanation for low receptor occupancy and early clinical relapse upon withdrawal of clozapine or quetiapine. Am J Psychiatry 1999; 156: 876-884.
121. Burki HR: Effects of fluperlapine on dopaminergic systems in rat brain. Psychopharmacology (Berl) 1986; 89: 77-84.
122. Kapur S, Zipursky R, Jones C, Shammi CS, Remington G, Seeman P: A positron emission tomography study of quetiapine in schizophrenia: A preliminary finding of an antipsychotic effect with only transiently high dopamine D 2 receptor occupancy. Arch Gen Psychiatry 2000; 57: 553-559.
123. Rangno RE, Nattel S, Lutterodt A: Prevention of propranolol withdrawal mechanism by prolonged small dose propranolol schedule. Am J Cardiol 1982; 49: 828-833.
124. Rangno RE, Langlois S: Comparison of withdrawal phenomena after propranolol, metoprolol and pindolol. Br J Clin Pharmacol 1982; 13: 345S-351S.
125. Gilligan DM, Chan WL, Stewart R, Oakley CM: Adrenergic hypersensitivity after betablocker withdrawal in hypertrophic cardiomyopathy. Am J Cardiol 1991; 68: 766-772.
126. Ashton H: Protracted withdrawal syndromes from benzodiazepines. J Subst Abuse Treat 1991; 8: 19-28.
127. Fava GA, Bernardi M, Tomba E, Rafanelli C: Effects of gradual discontinuation of selective serotonin reuptake inhibitors in panic disorder with agoraphobia. Int J Neuropsychopharmacol 2007; 10: 835-838.
128. Belaise C, Gatti A, Chouinard VA, Chouinard G: Patient online report of selective serotonin reuptake inhibitor-induced persistent postwithdrawal anxiety and mood disorders. Psychother Psychosom 2012; 81: 386-388.
129. Belaise C, Gatti A, Chouinard VA, Chouinard G: Persistent postwithdrawal disorders induced by paroxetine, a selective serotonin reuptake inhibitor, and treated with specific cognitive behavioral therapy. Psychother Psychosom 2014; 83: 247-248.
130. Shoenberger D: Discontinuing paroxetine: A personal account. Psychother Psychosom 2002; 71: 237-238.
131. Chouinard G, Annable L, Ross-Chouinard A, Nestoros JN: Factors related to tardive dyskinesia. Am J Psychiatry 1979; 136: 79-82.
132. Christensen AV, Fjalland B, Nielsen IM: On the supersensitivity of dopamine receptors, induced by neuroleptics. Psychopharmacology (Berl) 1976; 48: 1-6.
133. Chouinard G, Jones BD: Early onset of tardive dyskinesia: case report. Am J Psychiatry 1979; 136: 1323-1324.
134. Chouinard G, Boisvert D, Bradwejn J: Tardive dyskinesia in a nonpsychiatric patient due to short-Term use of a neuroleptic/anticholinergic combination drug. Can Med Assoc J 1982; 126: 821-822, 827.
135. Tarazi FI, Zhang K, Baldessarini RJ: Longterm effects of olanzapine, risperidone, and quetiapine on dopamine receptor types in regions of rat brain: implications for antipsychotic drug treatment. J Pharmacol Exp Ther 2001; 297: 711-717.
136. Kusumi I, Takahashi Y, Suzuki K, Kameda K, Koyama T: Differential effects of subchronic treatments with atypical antipsychotic drugs on dopamine D 2 and serotonin 5-HT 2A receptors in the rat brain. J Neural Transm (Vienna) 2000; 107: 295-302.
137. Brunelin J, dAmato T, Van Os J, Costes N, Suaud Chagny MF, Saoud M: Increased left striatal dopamine transmission in unaffected siblings of schizophrenia patients in response to acute metabolic stress. Psychiatry Res 2010; 181: 130-135.
138. Kapur S, Zipursky R, Jones C, Remington G, Houle S: Relationship between dopamine D 2 occupancy, clinical response, and side effects: A double-blind PET study of first-episode schizophrenia. Am J Psychiatry 2000; 157: 514-520.
139. Gardos G, Cole JO, Tarsy D: Withdrawal syndromes associated with antipsychotic drugs. Am J Psychiatry 1978; 135: 1321-1324.
140. Kimura H, Kanahara N, Watanabe H, Iyo M: Potential treatment strategy of risperidone in long-Acting injectable form for schizophrenia with dopamine supersensitivity psychosis. Schizophr Res 2013; 145: 130-131.
141. Wadenberg ML, Kapur S, Soliman A, Jones C, Vaccarino F: Dopamine D 2 receptor occupancy predicts catalepsy and the suppression of conditioned avoidance response behavior in rats. Psychopharmacology (Berl) 2000; 150: 422-429.
142. Natesan S, Reckless GE, Nobrega JN, Fletcher PJ, Kapur S: Dissociation between in vivo occupancy and functional antagonism of dopamine D2 receptors: comparing aripiprazole to other antipsychotics in animal models. Neuropsychopharmacology 2006; 31: 1854-1863.
143. Van Putten T, May RP: "Akinetic depression" in schizophrenia. Arch Gen Psychiatry 1978; 35: 1101-1107.
144. Rifkin A, Quitkin F, Klein DF: Akinesia: A poorly recognized drug-induced extrapyramydal behavioral disorder. Arch Gen Psychiatry 1975; 32: 672-674.
145. Voruganti LP, Awad AG: Is neuroleptic dysphoria a variant of drug-induced extrapyramidal side effects? Can J Psychiatry 2004; 49: 285-289.
146. Margolese HC, Chouinard G, Walters Larach V, Beauclair L: Relationship between antipsychotic-induced akathisia and tardive dyskinesia and suicidality in schizophrenia: impact of clozapine and olanzapine. Acta Psychiatr Belg 2001; 101: 128-144.
147. Van Putten T, Mutalipassi LR, Malkin MD: Phenothiazine-induced decompensation. Arch Gen Psychiatry 1974; 30: 102-105.
148. Takeuchi H, Suzuki T, Uchida H, Watanabe K, Mimura M: Antipsychotic treatment for schizophrenia in the maintenance phase: A systematic review of the guidelines and algorithms. Schizophr Res 2012; 134: 219-225.
149. Valenti O, Cifelli P, Gill KM, Grace AA: Antipsychotic drugs rapidly induce dopamine neuron depolarization block in a developmental rat model of schizophrenia. J Neurosci 2011; 31: 12330-12338.
150. Benet LZ, Zia-Amirhosseini P: Basic principles of pharmacokinetics. Toxicol Pathol 1995; 23: 115-123.
151. Sheehan JJ, Reilly KR, Fu DJ, Alphs L: Comparison of the peak-To-Trough fluctuation in plasma concentration of long-Acting injectable antipsychotics and their oral equivalents. Innov Clin Neurosci 2012; 9: 17-23.
152. Piafsky KM: Disease-induced changes in the plasma binding of basic drugs. Clin Pharmacokinet 1980; 5: 246-262.
153. Lee LH, Choi C, Collier AC, Barr AM, Honer WG, Procyshyn RM: The pharmacokinetics of second-generation long-Acting injectable antipsychotics: limitations of monograph values. CNS Drugs 2015; 29: 975-983.
154. Ericson H, Radesater AC, Servin E, Magnusson O, Mohringe B: Effects of intermittent and continuous subchronic administration of raclopride on motor activity, dopamine turnover and receptor occupancy in the rat. Pharmacol Toxicol 1996; 79: 277-286.
155. Smith RC, Davis JM: Behavioral supersensitivity to apomorphine and amphetamine after chronic high dose haloperidol treatment. Psychopharmacol Commun 1975; 1: 285-293.
156. Fukushiro DF, Carvalho Rde C, Ricardo VP, Alvarez Jdo N, Ribeiro LT, Frussa-Filho R: Haloperidol (but not ziprasidone) withdrawal potentiates sensitization to the hyperlocomotor effect of cocaine in mice. Brain Res Bull 2008; 77: 124-128.
157. Carvalho RC, Fukushiro DF, Helfer DC, Callegaro-Filho D, Trombin TF, Zanlorenci LH, Sanday L, Silva RH, Frussa-Filho R: Long-Term haloperidol treatment (but not risperidone) enhances addiction-related behaviors in mice: role of dopamine D 2 receptors. Addict Biol 2009; 14: 283-293.
158. Montanaro N, DallOlio R, Gandolfi O, Vaccheri A: Differential enhancement of behavioral sensitivity to apomorphine following chronic treatment of rats with (-)-sulpiride and haloperidol. Eur J Pharmacol 1982; 81: 1-9.
159. Kapur S, VanderSpek SC, Brownlee BA, Nobrega JN: Antipsychotic dosing in preclinical models is often unrepresentative of the clinical condition: A suggested solution based on in vivo occupancy. J Pharmacol Exp Ther 2003; 305: 625-631.
160. McCreadie RG, Dingwall JM, Wiles DH, Heykants JJ: Intermittent pimozide versus fluphenazine decanoate as maintenance therapy in chronic schizophrenia. Br J Psychiatry 1980; 137: 510-517.
161. Remington G, Seeman P, Feingold A, Mann S, Shammi C, Kapur S: "Extended" antipsychotic dosing in the maintenance treatment of schizophrenia: A double-blind, placebocontrolled trial. J Clin Psychiatry 2011; 72: 1042-1048.
162. Tsuboi T, Suzuki T, Bies RR, Remington G, Pollock BG, Mimura M, Uchida H: Challenging the need for sustained blockade of dopamine D 2 receptor estimated from antipsychotic plasma levels in the maintenance treatment of schizophrenia: A single-blind, randomized, controlled study. Schizophr Res 2015; 164: 149-154.
163. Nyberg S, Farde L, Halldin C, Dahl ML, Bertilsson L: D 2 dopamine receptor occupancy during low-dose treatment with haloperidol decanoate. Am J Psychiatry 1995; 152: 173-178.
164. Uchida H, Suzuki T: Dose and dosing frequency of long-Acting injectable antipsychotics: A systematic review of PET and SPECT data and clinical implications. J Clin Psychopharmacol 2014; 34: 728-735.
165. Samaha AN: Can antipsychotic treatment contribute to drug addiction in schizophrenia? Prog Neuropsychopharmacol Biol Psychiatry 2014; 52: 9-16.
166. Samaha AN, Potvin S: Drugs of abuse and psychiatric disorders: neurobiological and clinical aspects. Prog Neuropsychopharmacol Biol Psychiatry 2014; 52: 1-3.
167. Correll CU, Leucht S, Kane JM: Lower risk for tardive dyskinesia associated with second-generation antipsychotics: A systematic review of 1-year studies. Am J Psychiatry 2004; 161: 414-425.
168. Li Z, Ichikawa J, Huang M, Prus AJ, Dai J, Meltzer HY: ACP-103, a 5-HT 2A/2C inverse agonist, potentiates haloperidol-induced dopamine release in rat medial prefrontal cortex and nucleus accumbens. Psychopharmacology (Berl) 2005; 183: 144-153.
169. Chouinard G: Effects of risperidone in tardive dyskinesia: An analysis of the Canadian multicenter risperidone study. J Clin Psychopharmacol 1995; 15: 36S-44S.
170. Kane JM, Honigfeld G, Singer J, Meltzer H: Clozapine in treatment-resistant schizophrenics. Psychopharmacol Bull 1988; 24: 62-67.
171. Seeman P, Lee T, Chau-Wong M, Wong K: Antipsychotic drug doses and neuroleptic/dopamine receptors. Nature 1976; 261: 717-719.
172. Seeman P: Dopamine D 2 receptors as treatment targets in schizophrenia. Clin Schizophr Relat Psychoses 2010; 4: 56-73.
173. Goldstein J, Macfadden W: Reply to article by Margolese and associates on tolerance and rebound during maintenance with quetiapine. J Clin Psychopharmacol 2004; 24: 102-103; author reply 103-104.
174. Meltzer HY, Alphs L, Green AI, Altamura AC, Anand R, Bertoldi A, Bourgeois M, Chouinard G, Islam MZ, Kane J, Krishnan R, Lindenmayer JP, Potkin S: Clozapine treatment for suicidality in schizophrenia: International Suicide Prevention Trial (InterSePT). Arch Gen Psychiatry 2003; 60: 82-91.
175. Fukushiro DF, Alvarez Jdo N, Tatsu JA, de Castro JP, Chinen CC, Frussa-Filho R: Haloperidol (but not ziprasidone) withdrawal enhances cocaine-induced locomotor activation and conditioned place preference in mice. Prog Neuropsychopharmacol Biol Psychiatry 2007; 31: 867-872.
176. Creese I, Snyder SH: Chronic neuroleptic treatment and dopamine receptor regulation. Adv Biochem Psychopharmacol 1980; 24: 89-94.
177. Severson JA, Robinson HE, Simpson GM: Neuroleptic-induced striatal dopamine receptor supersensitivity in mice: relationship to dose and drug. Psychopharmacology (Berl) 1984; 84: 115-119.
178. Seeman P, Corbett R, Van Tol HH: Atypical neuroleptics have low affinity for dopamine D 2 receptors or are selective for D 4 receptors. Neuropsychopharmacology 1997; 16: 93-110; discussion 111-135.
179. Meltzer HY, Matsubara S, Lee JC: The ratios of serotonin2 and dopamine2 affinities differentiate atypical and typical antipsychotic drugs. Psychopharmacol Bull 1989; 25: 390-392.
180. Urban JD, Clarke WP, von Zastrow M, Nichols DE, Kobilka B, Weinstein H, Javitch JA, Roth BL, Christopoulos A, Sexton PM, Miller KJ, Spedding M, Mailman RB: Functional selectivity and classical concepts of quantitative pharmacology. J Pharmacol Exp Ther 2007; 320: 1-13.
181. de Bartolomeis A, Tomasetti C, Iasevoli F: Update on the mechanism of action of aripiprazole: Translational insights into antipsychotic strategies beyond dopamine receptor antagonism. CNS Drugs 2015; 29: 773-799.
182. Urban JD, Vargas GA, von Zastrow M, Mailman RB: Aripiprazole has functionally selective actions at dopamine D 2 receptor-mediated signaling pathways. Neuropsychopharmacology 2007; 32: 67-77.
183. Burris KD, Molski TF, Xu C, Ryan E, Tottori K, Kikuchi T, Yocca FD, Molinoff PB: Aripiprazole, a novel antipsychotic, is a high-Affinity partial agonist at human dopamine D 2 receptors. J Pharmacol Exp Ther 2002; 302: 381-389.
184. Di Lorenzo R, Amoretti A, Forghieri M, Fiorini F, Genedani S, Rigatelli M: Aripiprazole: effectiveness and safety under naturalistic conditions. Exp Clin Psychopharmacol 2007; 15: 569-575.
185. Marder SR, McQuade RD, Stock E, Kaplita S, Marcus R, Safferman AZ, Saha A, Ali M, Iwamoto T: Aripiprazole in the treatment of schizophrenia: safety and tolerability in short-Term, placebo-controlled trials. Schizophr Res 2003; 61: 123-136.
186. Gorwood P: Meeting everyday challenges: Antipsychotic therapy in the real world. Eur Neuropsychopharmacol 2006; 16(suppl 3): S156-S162.
187. Ishigooka J, Nakamura J, Fujii Y, Iwata N, Kishimoto T, Iyo M, Uchimura N, Nishimura R, Shimizu N, Group AS: Efficacy and safety of aripiprazole once-monthly in Asian patients with schizophrenia: A multicenter, randomized, double-blind, non-inferiority study versus oral aripiprazole. Schizophr Res 2015; 161: 421-428.
188. Sultan S, Chouinard G, Beaudry P: Antiepileptic drugs in the treatment of neurolepticinduced supersensitivity psychosis. Prog Neuropsychopharmacol Biol Psychiatry 1990; 14: 431-438.
189. Goddard GV, McIntyre DC, Leech CK: A permanent change in brain function resulting from daily electrical stimulation. Exp Neurol 1969; 25: 295-330.
190. Moskovitz C, Moses H 3rd, Klawans HL: Levodopa-induced psychosis: A kindling phenomenon. Am J Psychiatry 1978; 135: 669-675.
191. Post RM, Kopanda RT, Black KE: Progressive effects of cocaine on behavior and central amine metabolism in rhesus monkeys: relationship to kindling and psychosis. Biol Psychiatry 1976; 11: 403-419.
192. Chouinard G, Beauclair L, Belanger MC: Gabapentin: long-Term antianxiety and hypnotic effects in psychiatric patients with comorbid anxiety-related disorders. Can J Psychiatry 1998; 43: 305.
193. Kolivakis TT, Beauclair L, Margolese HC, Chouinard G: Long-Term lamotrigine adjunctive to antipsychotic monotherapy in schizophrenia: further evidence. Can J Psychiatry 2004; 49: 280.
194. Chouinard G, Vainer JL, Belanger MC, Turnier L, Beaudry P, Roy JY, Miller R: Risperidone and clozapine in the treatment of drug-resistant schizophrenia and neuroleptic-induced supersensitivity psychosis. Prog Neuropsychopharmacol Biol Psychiatry 1994; 18: 1129-1141.
195. Kristensen D, Hageman I, Bauer J, Jorgensen MB, Correll CU: Antipsychotic polypharmacy in a treatment-refractory schizophrenia population receiving adjunctive treatment with electroconvulsive therapy. J ECT 2013; 29: 271-276.
196. McGarvey KA, Zis AP, Brown EE, Nomikos GG, Fibiger HC: ECS-induced dopamine release: effects of electrode placement, anticonvulsant treatment, and stimulus intensity. Biol Psychiatry 1993; 34: 152-157.
197. Nakata Y, Kanahara N, Kimura H, Watanabe H, Iyo M: Efficacy of clozapine on dopamine supersensitivity psychosis in schizophrenia. Int Clin Psychopharmacol 2017; 32: 169-173.
198. Louza MR, Bassitt DP: Maintenance treatment of severe tardive dyskinesia with clozapine: years follow-up. J Clin Psychopharmacol 2005; 25: 180-182.
199. Weber J, McCormack PL: Asenapine. CNS Drugs 2009; 23: 781-792.
200. Shahid M, Walker GB, Zorn SH, Wong EH: Asenapine: A novel psychopharmacologic agent with a unique human receptor signature. J Psychopharmacol 2009; 23: 65-73.
201. Rajkumar RP: Supersensitivity psychosis and its response to asenapine in a patient with delusional disorder. Case Rep Psychiatry 2014; 2014: 215732.
202. Matteo P, Mula M, Basaglia C, Favaretto E, Schwitzer J: Asenapine after clozapine: is possible? Eur Psychiatry 2013; 28: 1.
203. UpToDate: Asenapine: Drug Information. Alphen aan den Rijn, Wolters Kluwer, 2017.
204. Kokare CK, Tagalpallewar AA, Aragade PS, Bagul US, Bacchav RK, Nanjwade BK: Formulation, evaluation and optimization of asenapine maleate fast mouth dissolving film. J Pharm Sci Pharmacol 2015; 2: 194-207.
205. Huang M, Kwon S, Oyamada Y, Rajagopal L, Miyauchi M, Meltzer HY: Dopamine D 3 receptor antagonism contributes to blonanserin-induced cortical dopamine and acetylcholine efflux and cognitive improvement. Pharmacol Biochem Behav 2015; 138: 49-57.
206. Huang M, Panos JJ, Kwon S, Oyamada Y, Rajagopal L, Meltzer HY: Comparative effect of lurasidone and blonanserin on cortical glutamate, dopamine, and acetylcholine efflux: role of relative serotonin (5-HT) 2A and DA D 2 antagonism and 5-HT 1A partial agonism. J Neurochem 2014; 128: 938-949.
207. Tachibana M, Niitsu T, Watanabe M, Hashimoto T, Kanahara N, Ishikawa M, Iyo M: Effectiveness of blonanserin for patients with drug treatment-resistant schizophrenia and dopamine supersensitivity: A retrospective analysis. Asian J Psychiatr 2016; 24: 28-32.
208. Inoue T, Osada K, Tagawa M, Ogawa Y, Haga T, Sogame Y, Hashizume T, Watanabe T, Taguchi A, Katsumata T, Yabuki M, Yamaguchi N: Blonanserin, a novel atypical antipsychotic agent not actively transported as substrate by P-glycoprotein. Prog Neuropsychopharmacol Biol Psychiatry 2012; 39: 156-162.
209. Chouinard G, Annable L, Ross-Chouinard A, Holobow N: A ten-year follow-up of supersensitivity psychosis. Biol Psychiatry 1990; 27: 110A.
210. Margolese HC, Chouinard G, Kolivakis TT, Beauclair L, Miller R: Tardive dyskinesia in the era of typical and atypical antipsychotics. Part 1: pathophysiology and mechanisms of induction. Can J Psychiatry 2005; 50: 541-547.
211. Margolese HC, Chouinard G, Kolivakis TT, Beauclair L, Miller R, Annable L: Tardive dyskinesia in the era of typical and atypical antipsychotics. Part 2: incidence and management strategies in patients with schizophrenia. Can J Psychiatry 2005; 50: 703-714.
212. de Montigny C, Chouinard G, Annable L: Ineffectiveness of deanol in tardive dyskinesia: A placebo controlled study. Psychopharmacology (Berl) 1979; 65: 219-223.
213. Chouinard G, De Montigny C, Annable L: Tardive dyskinesia and antiparkinsonian medication. Am J Psychiatry 1979; 136: 228-229.
214. Dyer C: European court upholds UK ban on Halcion. BMJ 1999; 318: 418.
215. Schooler N, Rabinowitz J, Davidson M, Emsley R, Harvey PD, Kopala L, McGorry PD, Van Hove I, Eerdekens M, Swyzen W, De Smedt G; Early Psychosis Global Working Group: Risperidone and haloperidol in first-episode psychosis: A long-Term randomized trial. Am J Psychiatry 2005; 162: 947-953.
216. Furberg CD, Pitt B: Withdrawal of cerivastatin from the world market. Curr Control Trials Cardiovasc Med 2001; 2: 205-207.
217. Chouinard VA, Pingali SM, Chouinard G, Henderson DC, Mallya SG, Cypess AM, Cohen BM, Ongur D: Factors associated with overweight and obesity in schizophrenia, schizoaffective and bipolar disorders. Psychiatry Res 2016; 237: 304-310.
218. McGuinness SM, Johansson R, Lundstrom J, Ross D: Induction of apoptosis by remoxipride metabolites in HL60 and CD34+/CD19-human bone marrow progenitor cells: potential relevance to remoxipride-induced aplastic anemia. Chem Biol Interact 1999; 121: 253-265.
219. Glassman AH, Bigger JT Jr: Antipsychotic drugs: prolonged QTc interval, torsade de pointes, and sudden death. Am J Psychiatry 2001; 158: 1774-1782.
220. Roden DM: Drug-induced prolongation of the QT interval. N Engl J Med 2004; 350: 1013-1022.
221. Isbister GK, Murray L, John S, Hackett LP, Haider T, OMullane P, Gosselin S, Daly F: Amisulpride deliberate self-poisoning causing severe cardiac toxicity including QT prolongation and torsades de pointes. Med J Aust 2006; 184: 354-356.
222. Leucht S, Cipriani A, Spineli L, Mavridis D, Orey D, Richter F, Samara M, Barbui C, Engel RR, Geddes JR, Kissling W, Stapf MP, Lassig B, Salanti G, Davis JM: Comparative efficacy and tolerability of 15 antipsychotic drugs in schizophrenia: A multiple-Treatments metaanalysis. Lancet 2013; 382: 951-962.